Objective: Recombinant human bone morphogenetic protein-2 (rhBMP-2) has been shown to enhance new bone formation in fracture and bone defect models in both normal and diabetic rats. Effects of rhBMP-2 in a segmental femoral defect model in diabetes mellitus (DM) BB Wistar rats have not been reported.
INTRODUCTION
Despite ongoing advances in orthopedics to enhance bone healing, about 5% to 10% of fractures still develop delayed union or nonunion. 1 A multitude of factors are known to play a role in causing delayed union and nonunions, including age, smoking, medications, and certain systemic diseases. Among this array of factors, diabetes mellitus (DM) is one systemic disease that has profound deleterious effect on bone healing. Association of DM with delayed union and nonunion after fracture and elective arthrodesis has led to further research into the role of potential adjuncts, that is, growth factor augmentation, in the clinical setting. The clinical importance of DM cannot be overstated with the United States alone having over 21 million DM patients and an additional 500,000 new cases diagnosed each year. 2 Several animal and clinical studies have documented the association between DM and impaired bone healing. Macey et al 3 showed that the fracture callus from the untreated DM rats had a 29% decrease in tensile strength and a 50% decrease in stiffness compared with non-DM rats 2 weeks after the production of a closed fracture. Herbsman et al 4 found a significant reduction in the tensile strength of a fibula fracture in an alloxan-induced diabetic rat model 4 weeks post fracture.
Similar findings have been reported in several clinical studies. [5] [6] [7] In addition to delayed healing, the rate of complication is also reported to be higher in DM patients. Three retrospective studies have evaluated complications after elective arthrodesis in DM patients. Although these patients represent a subpopulation of diabetics with neuropathy, the noted increased incidence of delayed union, nonunion, and pseudoarthrosis was highly significant in DM patient undergoing elective arthrodesis. [8] [9] [10] Another study analyzed the predisposing factors to nonunion after arthrodesis. Perlman and Thordarson 11 compared the results of ankle fusion in several nonunion risk groups. They found a higher incidence of nonunion in attempted arthrodesis in DM patients when compared with non-DM patients. Three of 8 nonneuropathic patients undergoing arthrodesis resulted in nonunion. Nonneuropathic patients with major medical problems including renal failure, DM, and alcohol abuse (11/13 patients, 85%) were noted to have a significant risk of nonunion (P , 0.04) compared with those with no associated medical problems. 11 Few studies have explored the effect of locally applied recombinant human bone morphogenetic protein-2 (rhBMP-2) upon non-DM osseus healing in a rat bone defect model. Yasko et al 12 , using inactive demineralized rat bone matrix as a carrier, analyzed 2 dosages, 11 mg and 1.4 mg of rhBMP-2. With the higher dose (11mg of rhBMP-2), osseous union was observed at 3 weeks in 3 of 10 cases. At 9 weeks, union rate was 80%. Mechanical parameters of torque to failure and stiffness reached 68% and 85%, respectively, compared with the intact contralateral femur. In contrast, no union was observed in the group with 1.4 mg rhBMP or carrier-alone group at 9 weeks. 12 Lee et al 13 used poly(lactic-co-glycolic acid) particles in blood clot as carrier for 9.3 mg and 0.93 mg of rhBMP-2 for analysis at 9 weeks. With the 9.3 mg of rhBMP-2, union rate was 100% and the torque failure and stiffness were 60% and 95% of contralateral limb, respectively, at 9 weeks. With the 0.93 mg of rhBMP-2, union rate was 67% and the torque to failure and stiffness were 20% and 47% that of the contralateral limb, respectively. Ohura et al 14 used b-tricalcium phosphate-monocalcium phosphate monohydrate as carrier for 6.28 mg and 1.26 mg of rhBMP-2 for analysis at 9 weeks. With the 6.28 mg rhBMP dosage, Ohura observed a large bone shell forming around the defect, resulting in osseous union in all cases within 3 weeks. With the 6.28 mg of rhBMP-2, union rate was 100% and the torque to failure and stiffness were 99% and 141% that of contralateral limb, respectively. With the 1.26 mg of rhBMP-2, union rate was 40% and the torque to failure was 41% that of contralateral limb, respectively. 14 To our present knowledge, no published study exists to determine the effects of rhBMP-2 in the presence of systemic disease like DM upon a segmental defect model. We hypothesized that DM would result in impaired new bone formation in femoral segmental defect compared with non-DM state. In addition, we hypothesized that rhBMP-2 would accelerate new bone formation in non-DM rats and normalize the impaired new bone formation in DM rats to the levels of non-DM rats. Our study investigated the effects of DM on femoral segmental defect model and more importantly assessed the effects of rhBMP-2 upon bone regeneration.
MATERIALS AND METHODS

Study Design
A segmental femoral defect rat model was used to study the effects of DM on new bone formation with and without rhBMP-2. A 3-mm mid-diaphyseal segment of bone was removed from the right femur of BB Wistar rats and replaced with a collagen sponge soaked with either buffer or rhBMP-2. The study was evaluated and approved by our Institutional Animal Care and Use Committee.
Microradiographs were obtained post surgery on a biweekly basis to examine the progression of new bone formation in the defect. The new bone formation was quantified on radiographs using a numerical scoring system, 15 on a scale of 0-6, with 0 for no radiographic evidence of new bone and 6 for complete bone bridging with remodeling.
Histomorphometric analysis was performed at 3 and 6 weeks post surgery. After sacrifice of the rats, the femurs were extracted, reradiographed under a higher magnification, and prepared for undecalcified histology. New bone formation and incorporation were evaluated and analyzed statistically. The neoangiogenesis in the healing callus was assessed with platelet endothelial cell adhesion molecule (PECAM-I) (monoclonal mouse anti-rat CD-31 antibody) staining at 3 weeks time point.
Mechanical testing was performed on 8 specimens at a 9-week time point.
Experimental Groups
A total number of 79 BB Wistar rats were used in the project. Of these 79 rats, 62 were used in final data analysis: 47 for histomorphometric analysis, 7 for PECAM-1 staining, and 8 for mechanical testing (Table 1) . Seventeen rats were excluded during study period due to complications; 1 due to anesthetic overdose, 1 secondary to the development of deep infection, 2 due to inappropriate date of sacrifice, 2 due to intraoperative complications, and 1 secondary to hardware failure or screw loosening after surgery. In 10, the slides were discarded due to poor histologic sections. Of these 17 rats, 10 were in the non-DM group and 7 were in the DM group.
DM Animal Model
In previous studies, experimental DM was induced with cytotoxic agents (alloxan, streptozotocin) that preferentially destroy pancreatic beta cells. These cytotoxins result in a clinical condition of insulin-dependent diabetes mellitus (type 1 DM). However, in this chemical-induced DM model, it is difficult to differentiate whether the deficient DM fracture healing process is due to the systemic effect of the cytotoxins and/or the DM condition. Second, in majority of studies, DM rats were treated with insulin in a manner not applicable to management of DM in humans. The untreated DM rats were treated with insulin only when the threat of ketoacidosis was present. These rats are noted to have substantial weight loss and are characterized by severe polyuria, ketonuria, and polyphagia. Thus, differentiating whether the deficient DM fracture healing process is due to malnutrition and/or the DM state itself is difficult to determine.
In contrast, our recently established DM femoral fracture model used male BB Wistar rat that is a close homology of juvenile type 1 DM. 16, 17 The onset of DM in BB Wistar rats is In addition to these groups, a total of 15 more DM rats were used. These DM rats were distributed for PECAM-1 staining for angiogenesis (7 at a 3-week time point) and mechanical testing (8 at a 9-week time point). spontaneous which confers advantages over the viral, chemical, or immunologic induction of DM. The BB Wistar rat develops DM through an autoimmune selective destruction of the pancreatic beta cells (intense insulinitis). As a result of insulinitis, within 7 days of the onset of glycosuria, the pancreatic beta cells are completely destroyed and if untreated, marked body wasting (including fat and muscle tissue), dehydration, and ketosis supervene. Death usually results within 5-10 days after onset if untreated by appropriate dosage of insulin. The male BB Wistar rats can be either diabetes resistant (non-DM) or DM prone. Of the DM-prone BB Wistar rats, 85% would develop DM on average at about 75 days of age. Because the DM-prone BB Wistar rat represents only a close homology to juvenile type 1 DM, the information must be interpreted with caution because this does not reflect the more clinically common adult onset insulin resistance type 2 DM.
In our study, urine from the DM BB Wistar rats was checked for glycosuria 3 times a week. Once glycosuria was detected, blood specimens obtained from tail veins were tested for blood glucose (BG) levels. If the BG value exceeded 150 mg/dL, an insulin implant (LINPLANT) was aseptically placed subcutaneously (SC) in the dorsal neck to provide constant insulin release for approximately 30 days. DM rats were aimed to be maintained with BG levels close to 300 mg/dL to simulate a poorly controlled DM with glycosuria but no sign of ketonuria. All newly turned DM rats were evaluated again in the first 24 hours after SC insulin implant insertion for BG level. If the desired BG level was not achieved, an additional amount of insulin implant was given to achieve the appropriate level. The BG levels were evaluated twice a week for the appropriate level of BG control.
Surgical Model
A rat segmental femoral defect model (3 mm) was used for this study, which is a load-bearing defect model. In the literature, many different sizes (4, 5, 6 , and 8 mm) segmental defects in rats have been described. 12, 14, [18] [19] [20] [21] [22] [23] [24] [25] [26] In our study, a 3-mm segmental defect was selected.
Male DM BB Wistar rats approximately 120 days 6 7 days old were used for this study. The rats were maintained on rodent chow (Purina, Saint Louis, MO) and water ad libitum. A 3.0-mm segmental defect was created in the right femur of each rat.
For surgery, rats were anesthetized with an intraperitoneal injection of a combination of ketamine (50 mg/kg) and xylazine (10 mg/kg). A quarter of the same dose was administered throughout the procedure, as booster, if required. Before surgery, each rat also received an intramuscular injection of enrofloxacin (5 mg/kg) as prophylactic antibiotic. A local anesthetic (bupivacaine 0.5 mL) was also administered at surgery site immediately before surgery. One day postoperatively, the rats were given enrofloxacin SC, and if needed, buprenorphine (SC) 0.2 mg/kg.
After a surgical plane of anesthesia was induced, the right hind limb of the rat was shaved and prepared using standard surgical techniques. An anterolateral approach was used to expose the femur. After surgical exposure, a 3-mm mid-diaphyseal defect was created in the femur using an oscillating saw attached on 3M Mini-Driver with a K151 blade. A 4-hole custom fabricated high-density polyimide bone plate (DuPont-Small Parts, Inc, Miami Lakes, FL), measuring 21.5 3 2.1 mm, was used for fixation of the femur across the defect using two #0 (diameter 1.38 mm) stainless steel flat head screws (Small Parts, Inc, Miami Lakes, FL) on each side of the defect. The fixation was reinforced by wrapping, between each set of screws on either side of defect, two 2-0 surgical steel monofilament cerclage wires (Ethi-Pack pre-cut sutures; Ethicon Inc, Somerville, NJ) braided together.
After fixation, absorbable collagen sponge (Absorbable Collagen Sponge (ACS); Medtronic, Memphis, TN) (dry state, size 8 3 6 3 3.5 mm) soaked with either buffer (each milliliter of buffer contains: 5.0 mg of sucrose, normal form; 25 mg of glycine, USP; 3.7 mg of L-glutamic acid, Fluid Catalytic Cracking; 0.1 mg of sodium chloride, United States Pharmacopeia; 0.1 mg of polysorbate 80, NF; and 1 mL of sterile water) or rhBMP-2 [0.05 mL (11.0 mg) at concentration 0.22 mg/dL], was implanted in the defect. The collagen sponge was soaked with buffer or rhBMP-2 for a minimum of 20 minutes before implantation. Finally, the wound was closed in layers and a topical antibiotic ointment was applied (neomycin sulfate 5 mg, polymyxin B sulfate equal to 5000 polymyxin B units, and bacitracin zinc equal to 400 bacitracin units).
Microradiographic Evaluation
Serial radiographs were done on all operated rats on the day of surgery and thereafter every 2 weeks until sacrifice. The radiographs were obtained using a Packard model 804 Faxitron and Kodak MiniR-2000 mammography film.
The rats were anesthetized with same anesthesia protocol as described above for surgery, and a lateral view of the femur was obtained by placing the rat prone on the radiograph plate. In addition, magnified radiographs were obtained of the post sacrifice extracted femora. The exposures for radiographs were performed at 55 kVp for 30 seconds.
The qualitative analysis of new bone formation was done using a numerical scoring system 15 by 2 independent observers. Using this scoring system, the radiographs were graded from a value of 0 for no change from immediate postoperative appearance to a maximum value of 6 for complete bridging of defect by uniform new bone. The final score for each animal was obtained by averaging the scores from 2 independent observers.
Histology and Histomorphometry
After sacrifice, the right side femora were extracted from each animal. The extracted femurs were then processed for histology by fixation in formalin, followed by dehydration in increasing concentration of ethanol (70%-100%) and finally embedding in hand polymethylmethacrylate (hPMMA). Once embedded in polymethylmethacrylate (PMMA), the samples were cut into thin sagittal sections using a low-speed diamond saw (Isomet 11-1180 Low Speed Saw; Buehler LTD, Evanston, IL) of approximately 300 mm. The sections were then glued to microscope slides and ground (Handimet 2 Roll Grinder, Buehler LTD) to a thickness of approximately 100 mm. Finally, the glued sections were polished on a rotating The slides were stained with a combination of Stevenel blue and Van Gieson picrofuschin. After staining with Stevenel blue and Van Gieson picrofuschin, the mineralized tissue appears orange to red, collagen green to green-blue, osteoid yellow-green, and muscle fibers blue to blue-green.
The histomorphometric analysis was performed under microscope (Olympus SZX12; Olympus Opticals Co, LTD, Japan, Center Valley, DA) connected via a camera (Nikon DXM1200f) to a personal computer. The slide images were analyzed using Image Pro Plus software. The quantitative analysis of new bone area was performed using techniques described by Harten et al. 27 Seven different areas were measured on the slide (Fig. 1 ) and grouped into 3 zones: periosteal bone (1), endosteal bone (2), and defect bone (3). The total new bone area was calculated by summing the aforementioned areas.
PECAM-1 Staining
An assessment of neovascularization was done on 7 specimens at 3-week time point by PECAM-1 immunohistochemical staining of tissue. Samples were processed using a standard decalcified bone protocol followed by paraffin embedding and sagittal sectioning at 6 mm in preparation for immunohistochemical staining. [28] [29] [30] Paraffin was removed from tissue section slides with xylene. The tissue sections then were rehydrated through a decreasing ethanol to water series. The tissue sections were washed in phosphate-buffered saline, and endogenous peroxidase was blocked using a solution of 0.5% H 2 O 2 /H 2 O for 10 minutes and washed 3 3 5 minutes. The tissue sections were incubated in 1.5% blocking serum for 1 hour in moist chamber. The primary antibody used was mouse anti-rat CD-31 monoclonal antibody (BD Pharmingen, San Jose, CA). The primary antibody was detected using an amplified horseradish peroxidase staining procedure (ABC Staining kit; Santa Cruz Biotechnology, Santa Cruz, CA), counterstained with methylgreen and mounted for microscopic examination.
Mechanical Testing
Nine weeks after surgery, rats were killed, and the femora were resected and stripped off the surrounding soft tissue, polyimide plates, and screws. The femora were then evaluated by manual palpation for bony healing. The proximal and distal ends of each bone were embedded in wood's metal alloy (50% bismuth, 25% lead, 12.5% tin, and 12.5% cadmium) blocks, and the diaphysis was wrapped in gauze soaked with normal saline. Femora were then mounted on a combined axial motion and torsional testing jig that was attached to a universal testing machine (MTS Ò , Minneapolis, MN). The mounted bones were subjected to torque until bone failure was observed. Peak torque (NÁm), torsional rigidity (NÁm/deg), shear modulus (NÁm
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), and maximum shear stress (MPa) parameters were recorded. Femurs that were frank nonunions were not tested and were given the value of zero.
Statistics
Areas of new bone on histomorphometry were statistically analyzed in both control and experimental groups based on location (defect, endosteal, periosteal) and total amount of new bone area regardless of location. The statistical analyses for histomorphometry and radiographic scoring were performed using 1-way analysis of variance with the Bonferroni adjustment to account for multiple comparisons at each time points (3 weeks and 6 weeks). The data from PECAM-I staining (3 weeks) and mechanical testing (9 weeks) were analyzed using the Student t test with significance set at P , 0.05.
RESULTS
General Health
The DM animal BG is monitored as a parameter of their general health before and after surgery. The average BG value for the DM rats in buffer-treated group was 406.8 (range 298-482) mg/dL in 3-week group and 361.33 (range 319-408) mg/dL in 6-week group. In rhBMP-2-treated rats, the values were 381.2 (range 322-455) mg/dL in the 3-week group and 334.12 (range 246-472) mg/dL in the 6-week group. All DM rats maintained average BG values over 300 mg/dL during the entire period of the study ( Table 2) .
The body weight was measured for all the rats on the day of surgery and on the day of sacrifice to assess the general health post surgery. The average body weight at the time of surgery were 428.13 g (SD = 36.6) in non-DM and 356.51 g (SD = 58.4) in DM rats, and on day of sacrifice, the average body weights were 453.54 g (SD = 58.4) and 378.60 g (SD = 51.0), respectively. The average gain in body weight post surgery for non-DM rats was 26.45 g (SD = 7.9) and for DM rats was 27.40 g (SD = 30.8) ( Table 3) .
Radiographic Scoring
A qualitative analysis of the new bone formation on radiographs was done for all the rats by 2 independent observers. The scoring was done on the radiographs taken on the day of sacrifice. The average scores for non-DM rats (Fig.  4 ) were 1.3 (3 weeks) and 1.75 (6 weeks) in the buffer group The data represent average value 6 standard deviation. and 3.16 (3 weeks) and 4.0 (6 weeks) in the rhBMP-2 group. In DM rats (Fig. 5) , the average scores were 1.5 (3 weeks) and 1.16 (6 weeks) in the buffer group and 2.33 (3 weeks) and 4.21 (6 weeks) in the rhBMP-2 group. When comparing average scores between buffer and rhBMP-2 groups, a statistically significant difference was observed in the non-DM group at 3 weeks (P = 0.012) and both non-DM and DM groups at 6 weeks (non-DM: P = 0.005, DM: P , 0.001). When comparing average scores between buffer and rhBMP-2 groups, no statistical significance was observed in the DM group at 3 weeks (P = 0.667) ( Table 4 ).
Histologic and Histomorphometric Analysis
The new bone area was assessed in 7 different areas on slide grouped into 3 zones, periosteal, endosteal, and defect bone to calculate the total new bone area. Individual assessment of these different zones revealed their relative contribution in total new bone area. The defect new bone contributed maximum to the total new bone area followed by periosteal new bone. The endosteal new bone contributed least to the total new bone area (Fig. 1) .
Comparison of New Bone Area in Bone Morphogenetic Protein-2-Treated Rats Versus Buffer-Treated Rats
Quantitative histomorphometric analysis showed statistically significant increase in amount of new bone area between rats treated with rhBMP-2 compared with rats treated with buffer at both 3 and 6 weeks. The difference was greater at 3 weeks time point as compared with 6 weeks time point (Table 5) .
Non-DM Groups
The average new bone area in Non DM rats (Fig. 2) ; P = 0.003).
DM Group
In DM rats (Fig. 3 ) also, the increase in average new bone area with rhBMP-2 was statistically significant compared with rats treated with buffer at both 3 weeks (7. 
Comparison of New Bone Area Between Non-DM and DM Rats Treated With Buffer
At 3 weeks, the DM rats initially showed a statistically significant decrease in new bone area compared with non-DM rats when treated with buffer alone before the Bonferroni adjustment (P = 0.048). Using the Bonferroni adjustment, the average new bone area at 3 weeks in buffer treated non-DM was 2.07 6 0.66 mm 2 compared with 0.84 6 0.39 mm 2 in DM rats, demonstrating a trend toward significance (P = 0.289). At 6 weeks, the corresponding values were 3.22 6 1.24 mm 2 and 3.01 6 2.06 mm 2 (P = 1.0) ( Table 6 ).
Comparison of New Bone Area Between Non-DM and DM Rats Treated With rhBMP-2
Both DM and non-DM rats treated with rhBMP-2 showed significant increase in the amount of new bone area compared with buffer-treated rats. At 3 weeks, the average new bone in non-DM rats treated with rhBMP-2 was 6.91 6 1.42 mm 2 and in DM rats was 7.89 6 1.0 mm 2 (P = 0.562). At 6 weeks, similar increase in new bone area was seen with average new bone being 7.38 6 0.86 mm 2 in non-DM and 7.16 6 2.44 mm 2 in DM rats (P = 1.0). At either time points (3 weeks and 6 weeks), no statistically significant difference was observed between DM and non-DM rats treated with rhBMP-2 ( Table 7) .
PECAM-1 Staining
Immunohistochemical staining for PECAM-1 was performed on 7 femora of DM rats (3 rhBMP-2-treated and 4 buffer-treated rats) to assess the neoangiogenesis at 3 weeks time point. Significantly, increased staining for CD31 was seen The data represent average value 6 standard deviation. *Represents values statistically higher than non-DM treated with buffer at 3 weeks, P , 0.001.
†Represents values statistically higher than non-DM treated with buffer at 6 weeks, P = 0.003.
‡Represents values statistically higher than DM treated with buffer at 3 weeks, P , 0.001. §Represents values statistically higher than DM treated with buffer at 6 weeks, P = 0.004.
q 2009 Lippincott Williams & Wilkins in DM rats treated with rhBMP-2 in comparison to buffertreated rats (Fig. 6) . The mean number of vessels in rhBMP-2-treated DM rats was 12.76 6 5.43/mm 2 compared with 4.49 6 1.89/mm 2 in buffer-treated DM rats (P = 0.034) ( Table 8) .
Mechanical Testing
Mechanical testing was done at 9 weeks time point on 8 DM rats, of which, 4 were treated with rhBMP-2 and 4 with buffer. All 4 buffer-treated DM rats went onto nonunion, therefore, the values for all parameters of mechanical testing was considered as 0. Mechanical testing results obtained from rhBMP-2-treated DM rats were compared statistically with buffer-treated rats. The peak torque (NÁm), torsional rigidity (NÁm/deg), and shear modulus parameters of mechanical testing showed statistically significant improvement over buffer-treated rats (Table 9 ). 
DISCUSSION
Bone morphogenetic proteins combined with different carrier materials, such as tricalcium phosphate, polylactic acid polymer, collagen, inactive demineralized bone matrix, and composites of these materials, have been shown to increase bone defects healing in several studies. 13, 14, [31] [32] [33] [34] In the present study, the rhBMP-2/collagen carrier-treated experimental groups were observed to have significantly increased bridging of the defects and increased radiographic scores and increased histomorphometric and mechanical testing parameters of new bone formation compared with the buffer/collagen-treated group in both DM and non-DM rats.
The radiographic, histomorphometric, and mechanical testing values obtained are comparable to the values seen in the literature regarding bone morphogenetic protein-2 augmentation in similar rat femur segmental model. 11, 12 In the present study, 11 mg of rhBMP-2 was used with ACS for implantation into the defect site, which is the dose comparable to dose used by Yasko et al 12 and Lee et al. 13 Despite the presence of DM, union rate and mechanical parameters observed at 9 weeks of our study were comparable with union rate and mechanical parameters seen in rhBMP-2 augmentation in non-DM studies. Similarly, ACS alone resulted in nonunion in all DM specimens, similar to the carrier alone results as observed by Yasko et al. 12 Quantitative histomorphometric analysis showed statistically significant increase in amount of new bone area between rats treated with rhBMP-2 compared with rats treated with buffer at both 3 and 6 weeks time points (Table 5 ). The increased new bone area seen on histomorphometry was associated with increased neoangiogenesis observed on PECAM-1 immunohistochemical staining for endothelial cells at a 3-week time point. Neoangiogenesis is an important factor in early cellular phase of bone healing, and the increased staining for PECAM-1 supplemented the increased new bone area observed on histomorphometry, especially at 3 weeks time point.
The significant difference in bone formation demonstrated in radiographic appearance was further evaluated with a previously described 6-point radiographic scoring system. 15 Different studies use different radiographic grading system which makes it difficult to compare the radiographic healing progress with other studies. In present study, radiographic union was observed in all (100%) rats, DM or non-DM, of our rhBMP-2 groups by 6 weeks, with significantly increased radiographic scores compared with controls (P , 0.001). Even though a statistically significant difference in new bone formation is seen on histomorphometry and PECAM-1 staining at 3 weeks, the radiographic score at 3 weeks did not achieve statistical significance in DM rats with and without rhBMP-2 treatment. The discrepancy may be because the 3 weeks time point in healing process is too early for a meaningful radiographic comparison between the 2 groups. Another possible explanation of this discrepancy is that the sample size used in this study was too small to detect a statistical significance at this time point.
Clearly, although DM has a known impact on osseous healing, its effect is ameliorated with the application of the rhBMP-2/collagen carrier and demonstrates a potential clinical role of this adjunct in the clinical arena. The mechanism through which DM impairs bone healing is still not completely understood. Several theories have been proposed implicating The data represent average value 6 standard deviation. *The Pvalue before Bonferroni adjustment = 0.048. hyperglycemia and the resulting production of advanced glycation end products (AGEs) and growth factor deficiency as major factors in DM-related impaired bone healing. [35] [36] [37] [38] [39] In non-DM animals, AGE treatment caused a dose-dependent reduction in bone healing. 36, 38 Other authors have focused on the deficiency of early critical growth factors like insulin-like growth factor, 40 basic fibroblast growth factor (bFGF), 40 transforming growth facor-beta, [41] [42] [43] [44] and platelet-derived growth factor (PDGF) 3 in DM leading to impaired bone healing.
Many adjuncts to osseous healing have been investigated to ameliorate the deleterious effects of DM in bone healing. Reports exist evaluating the use of recombinant human bFGF, local delivery of insulin, insulin-like growth factor, PDGF, the percutaneous injection/local application of platelet-rich plasma, and biodegradable microcapsules containing bone formation stimulant (TAK-778) for their role as adjuncts in DM bone healing. Kawaguchi et al 45 found decreased levels of bFGF in the DM rat fibula fracture callus, and exogenous application of rhFGF increased the levels of transforming growth facorbeta at the fracture site in DM rats and restored the volume and mineral content of diabetic callus. Gandhi et al 28 used a novel intramedullary insulin delivery system to investigate the potential direct effects of insulin on bone healing. Local insulin delivery at the fracture site normalized the early and late parameters of DM fracture healing without affecting the systemic parameters of BG. 28 Preliminary work in our laboratory has demonstrated the effectiveness of locally implanted recombinant human PDGF augmentation in significantly improving histomorphogenic and mechanical parameters, using the DM BB Wistar femur fracture model. Gandhi et al 46 reported locally injected platelet-rich plasma, a myriad of early critical growth factor, partially ameliorated impaired DM fracture healing using similar DM BB Wistar femur fracture model. Hoshino et al 47 reported that locally delivered microcapsules of TAK-778 enhanced fracture repair in streptozotocin-induced diabetic rats. TAK-778 increased the bending strength of diabetic bone at 4 weeks and 8 weeks. The fracture callus was remodeled, and cortical bony union was demonstrated in the TAK-778-treated diabetic group compared with the fibrous nonunion in diabetic-only group. It is noted that these adjunct studies are focused mainly on DM femur fracture model. The strength of our study lies in the fact that it is the first study to analyze the effects of DM in a segmental defect model and treated with the application of a local rhBMP-2 delivery system. Although our study initially revealed a significantly decreased amount of new bone formation in control DM rats compared with control non-DM rats at 3 weeks before the post hoc adjustment, this analysis only showed a trend toward significance after the Bonferroni adjustment. Further, no significant difference in new bone growth was seen between non-DM and DM rats at 6 weeks. We attribute this observation to the fact that DM may simply delay new bone formation. At a later time point, the amount of new bone formation may plateau leading to similar amounts of new bone between the 2 groups. Another possible explanation is that the sample size was too small to determine statistical significance. A single application of rhBMP-2 resulted in new bone formation in the DM group comparable to the non-DM group, thus demonstrating the ability of rhBMP-2 in negating the deleterious effects of DM on new bone formation. The clinical importance of this topic lies in the increasing number of DM patients living longer and enduring significant orthopaedic challenges, like a critical size defect after trauma or reconstructive surgery. This study demonstrated the effectiveness of rhBMP in the presence of DM in a segmental defect and provides insight in the potential role of rhBMP-2 in this difficult clinical application. It is difficult to determine how DM is actually influencing the bone healing process in this study, especially with the current sample size. We recommend additional studies to determine the effect of DM and how it influences the bone healing process. Additional studies may focus on application of temporal control of genetic protein release for the determination of which specific phase of bone remodeling is up-regulated. The data represent average value 6 standard deviation. The data represent average value 6 standard deviation and P value.
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